Traditional biomarkers, such as carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), have been widely used in clinical practice for predicting the prognosis of CRC patients [7], but they are known to have limited accuracy, with the area under the curve (AUC) of 0.597 and 0.710, respectively [8,9]. This evidence concerns the gene CEACAM5 and colorectal carcinoma.